NCT04615637 (NEW MEG) is a NA clinical trial of MEG recordings in Normal Subject, sponsored by Hospices Civils de Lyon.

Who is sponsoring NCT04615637?

NCT04615637 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT04615637?

Interventions in NCT04615637: MEG recordings.

What condition does NCT04615637 study?

NCT04615637 studies Normal Subject, Patient With Pharmaco-resistant Epilepsy.

Is NCT04615637 still recruiting?

NCT04615637 is currently status unknown. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT04615637: NEW MEG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Helium 4 Optically Pumped Magnetometers : a New Generation of Sensors for High Speed Functional Brain Imaging

Status unknown NA Last updated 16 February 2021

What this trial tests

NA trial testing MEG recordings in Normal Subject in 45 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 July 2023

1 July 2023

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	45
Start date	1 March 2021
Primary completion	1 July 2023
Estimated completion	1 July 2023
Sites	1 location across France

Drugs / interventions tested

MEG recordings

Conditions studied

Normal Subject — all drugs for Normal Subject →
Patient With Pharmaco-resistant Epilepsy — all drugs for Patient With Pharmaco-resistant Epilepsy →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 18 to 60, any sex, with Normal Subject or Patient With Pharmaco-resistant Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our goal is to perform a first evaluation of the capabilities of a new generation of non-invasive magnetoencephalography sensors (OPM He4) to record brain magnetic activities. The investigator will record 1) normal subjects stimulated with visual, auditory, somesthesic and motor stimuli and 2) epileptic patient. The investigator will compare the signal to noise ratio of the normal or pathological activities between classical MEG sensors and our OPM He4 prototype.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04615637 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04615637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing